Dr. Muhammad Daniyal
Department of Pediatrics, Hematology and Oncology, Penn State College of Medicine, Hershey, Pennsylvania, USA
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
13Years (2014-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications2 October 2017 in Biological Research
Journal Article
MAMuhammad Akram
Muhammad AkramMIMehwish Iqbal
Mehwish IqbalMuhammad DaniyalAKAsmat Ullah Khan
Asmat Ullah KhanBreast cancer remains a worldwide public health dilemma and is currently the most common tumour in the globe. Awareness of breast cancer, public attentiveness, and advancement in breast imaging has made a positive impact on recognition and screening of breast cancer. Breast cancer is life-threatening disease in females and the leading cause of mortality among women population. For the previous two decades, studies related to the breast cancer has guided to astonishing advancement in our understanding of the breast cancer, resulting in further proficient treatments. Amongst all the malignant diseases, breast cancer is considered as one of the leading cause of death in post menopausal women accounting for 23% of all cancer deaths. It is a global issue now, but still it is diagnosed in their advanced stages due to the negligence of women regarding the self inspection and clinical examination of the breast. This review addresses anatomy of the breast, risk factors, epidemiology of breast cancer, pathogenesis of breast cancer, stages of breast cancer, diagnostic investigations and treatment including chemotherapy, surgery, targeted therapies, hormone replacement therapy, radiation therapy, complementary therapies, gene therapy and stem-cell therapy etc for breast cancer.
22 January 2018 in Phytotherapy Research
Journal Article
MAMuhammad Akram
Muhammad AkramITImtiaz Mahmood Tahir
Imtiaz Mahmood TahirSSSyed Muhammad Ali Shah
Syed Muhammad Ali ShahZMZahed Mahmood
Zahed Mahmood
AAAwais Altaf
Awais Altaf
HMHuma Mehboob
Huma Mehboob +4
1 October 2019 in Biomaterials
Journal Article
BLBin Liu
Bin LiuWWWenmiao Wang
Wenmiao Wang
JFJialong Fan
Jialong Fan
YLYing Long
Ying Long
FXFeng Xiao
Feng Xiao
WWwei wang
wei wang +6
18 December 2014 in Asian Pacific Journal of Cancer Prevention
Journal Article
Muhammad DaniyalZSZamir Ali Siddiqui
Zamir Ali Siddiqui
MAMuhammad Akram
Muhammad AkramHAHafiz Asif
Hafiz AsifSSSabira Sultana
Sabira Sultana
AKAsmatullah Khan
Asmatullah Khan
Epidemiology, Etiology, Diagnosis and Treatment of Prostate Cancer Prostate cancer;etiology;epidemiology in worldwide prevalence;treatment;literature review Pakistan; Prostate cancer is more common in men over the age of 65 years. There are 15% cases with positive family history of prostate cancer Worldwide. Prostate cancer is the second leading cause of death among the U.S. men. Prostate cancer incidence is strongly related to age with the highest rates in older man. Globally millions of people are suffering from this disease. This study aims to provide awareness about prostate cancer as well as an updated knowledge about the epidemiology, etiology, diagnosis and treatment of prostate cancer.
11 November 2019 in Journal of Pharmacy and Pharmacology
Journal Article
MAMuhammad Akram
Muhammad AkramMRMuhammad Riaz
Muhammad Riaz
NMNaveed Munir
Naveed Munir
NANaheed Akhter
Naheed Akhter
SZSadia Zafar
Sadia Zafar
FKFahad Said Khan
Fahad Said Khan
+7
30 June 2020 in Current Medicinal Chemistry
Journal Article
Motivated by the accomplishment of carbon nanotubes (CNTs), graphene and graphene oxide (GO) has been widely investigated in the previous studies as an innovative medication nanocarrier for the loading of a variety of therapeutics as well as anti-cancer medications, poor dissolvable medications, antibiotics, antibodies, peptides, DNA, RNA and genes. Graphene provides the ultra-high drug-loading efficiency due to the wide surface area. Graphene and graphene oxide have been widely investigated for biomedical applications due to their exceptional qualities: twodimensional planar structure, wide surface area, chemical and mechanical constancy, sublime conductivity and excellent biocompatibility. Due to these unique qualities, GO applications provide advanced drug transports frameworks and transports of a broad range of therapeutics. In this review, we discussed the latest advances and improvements in the uses of graphene and GO for drug transport and nanomedicine. Initially, we have described what is graphene and graphene oxide. After that, we discussed the qualities of GO as a drug carrier, utilization of GO in drug transport applications, targeted drug transport, transport of anticancer medications, chemical control medicine releasee, co-transport of different medications, comparison of GO with CNTs, nano-graphene for drug transport and at last, we have discussed the graphene toxicity. Finally, we draw a conclusion of current expansion and the potential outlook for the future.
About Me
• Highly skilled scientist with extensive experience in cancer cellular and molecular biology particularly cancer cell signaling pathways, microRNA functional biology, genetics and stem cell biology.
• Extensive hands-on experience in
o Cell based assay, Proficient in ELISA, dot blot, Western blot (including high-throughput Jess), and cell cycle, apoptosis, proliferation, and colony formation assays.
o Genetic engineering Expertise in cloning, genetic construct development, gene silencing (siRNA, shRNA), transfection, stable cell line generation, and target gene/protein expression.
o Molecular Techniques: Skilled in qPCR, multicolor flow cytometry, kinase activity assays, molecular assay development, immunoprecipitation, immunofluorescence, immunohistochemistry, and luciferase assays
o Microscopy and Staining: Experience with confocal microscopy, H&E staining.
o Drug Studies: Involvement in drug screening, drug mechanism studies, and toxicity assays.
o Primary Cell Culture: Expertise in mammalian cell culture, including hematopoietic stem cells (HSCs), B-cells, T-cells, plasma cells.
o Cancer Research: Experienced in generating resistance cell line, cancer mouse models and performing assays related to cancer research.
• Proficient in various route of dosing/in vivo drug administration (Oral, Intra peritoneal (IP), subcutaneous (SC), intradermal (ID), intramuscular (IM) and intravenous (IV).
• Experience in developing Nano-drug delivery system for delivery of various drugs.
Social Links
